- Boehringer Ingelheim (Ridgefield, CT)
- …nonclinical safety programs to support the development of drug candidates from discovery to market authorization. The incumbent will be highly motivated and ... multiple therapeutic areas and modalities including small molecules, monoclonal antibody -based biotherapeutics, viral, and gene therapies. As the primary interface… more